The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
 
Nicola Normanno
Honoraria - AstraZeneca; Biocartis; Illumina; Incyte; Lilly; Merck Serono; MSD; MSD; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Bayer; Biocartis; Incyte; Novartis; Roche
Research Funding - AstraZeneca (Inst); Biocartis (Inst); Illumina (Inst); Incyte (Inst); Merck Serono (Inst); Qiagen (Inst); Roche (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Merck Serono
 
Anna Maria Rachiglio
No Relationships to Disclose
 
Riziero Esposito Abate
No Relationships to Disclose
 
Armando Orlandi
No Relationships to Disclose
 
Evaristo Maiello
No Relationships to Disclose
 
Giuseppe Maglietta
No Relationships to Disclose
 
Angela Damato
Travel, Accommodations, Expenses - Incyte; Ipsen; Janssen-Cilag; Lilly
 
Monica Rosaria Maiello
No Relationships to Disclose
 
Marianeve Carotenuto
No Relationships to Disclose
 
Maria Alessandra Calegari
No Relationships to Disclose
 
Lorenzo Antonuzzo
Honoraria - Amgen; AstraZeneca; Novartis; Roche
Consulting or Advisory Role - Merck Serono
 
Roberto Bordonaro
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
 
Maria Giulia Zampino
No Relationships to Disclose
 
Stefano Tamberi
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Antonio Avallone
Honoraria - Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; MSD Oncology
 
Tiziana Pia Latiano
No Relationships to Disclose
 
Emiliano Tamburini
Consulting or Advisory Role - Amgen; AstraZeneca; SERVIER
 
Carlo Antonio Barone
No Relationships to Disclose
 
Carmine Pinto
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Incyte; Ipsen; Janssen; Merck Serono; MSD; Novartis; Roche; SERVIER
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Incyte; Ipsen; Janssen; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; SERVIER
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Roche